ANIX
$2.89
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.
Intraday
Recent News
Anixa Biosciences AGM: Shareholders Back Directors as CEO Highlights CAR-T, Vaccine Progress
Anixa Biosciences (NASDAQ:ANIX) held its 2026 Annual Meeting of Stockholders via live webcast, outlining the results of shareholder votes and providing an operational update focused on the company’s clinical-stage oncology pipeline and partnership-driven strategy. Annual meeting votes and quorum Pr
Anixa Biosciences CEO Calls 2026 “Pivotal” as Breast Cancer Vaccine, Ovarian CAR-T Advance
Anixa Biosciences (NASDAQ:ANIX) Chairman and CEO Dr. Amit Kumar said the company views 2026 as a “pivotal year” as it advances two clinical-stage programs: a breast cancer vaccine being developed with the Cleveland Clinic and the U.S. Department of Defense, and a CAR-T cell therapy for terminally il
Here's Why We're Not Too Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Top Penny Stocks To Watch In November 2025
The U.S. stock market has seen a downturn following the end of the longest federal shutdown in history, with major indices slipping as technology shares led declines. Despite these challenges, opportunities remain for investors willing to explore smaller or newer companies often categorized under the term "penny stocks." These stocks can offer significant growth potential at lower price points, especially when they are backed by strong financials and solid fundamentals.
Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?
Here is how ANIXA BIOSCIENCES INC (ANIX) and Boston Scientific (BSX) have performed compared to their sector so far this year.